Do analysts rate CALT or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CALT or LWAC?

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Do analysts prefer LWAC or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, LWAC or AVTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is LWAC or AVTE more profitable?

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts rate LWAC or ELYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, LWAC or ELYM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is LWAC or ELYM more profitable?

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Eliem Therapeutics N/A -47.03% -45.97%

Do analysts rate SBTX or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, SBTX or LWAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Is SBTX or LWAC more profitable?

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% LightWave Acquisition N/A N/A N/A

Do analysts recommend NLTX or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NLTX or LWAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Is NLTX or LWAC more profitable?

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% LightWave Acquisition N/A N/A N/A

LightWave Acquisition (LWAC) Competitors

$10.29 +0.01 (+0.10%)

As of 10:18 AM Eastern

Compare

LWAC vs. CALT, AVTE, ELYM, SBTX, and NLTX

Should you buy LightWave Acquisition stock or one of its competitors? MarketBeat compares LightWave Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LightWave Acquisition include Calliditas Therapeutics AB (publ) (CALT), Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), Silverback Therapeutics (SBTX), and Neoleukin Therapeutics (NLTX).

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
LightWave Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

LightWave Acquisition has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. LightWave Acquisition's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
LightWave Acquisition	N/A	N/A	N/A

Summary

LightWave Acquisition beats Calliditas Therapeutics AB (publ) on 4 of the 7 factors compared between the two stocks.

How does LightWave Acquisition compare to Aerovate Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, LightWave Acquisition's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
LightWave Acquisition	Neutral
Aerovate Therapeutics	Neutral

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

LightWave Acquisition beats Aerovate Therapeutics on 3 of the 3 factors compared between the two stocks.

How does LightWave Acquisition compare to Eliem Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, LightWave Acquisition's average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score.

Company	Overall Sentiment
LightWave Acquisition	Neutral
Eliem Therapeutics	Neutral

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

LightWave Acquisition beats Eliem Therapeutics on 3 of the 5 factors compared between the two stocks.

How does LightWave Acquisition compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
LightWave Acquisition	Neutral

74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
LightWave Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

LightWave Acquisition beats Silverback Therapeutics on 3 of the 5 factors compared between the two stocks.

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
LightWave Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
LightWave Acquisition	N/A	N/A	N/A

Summary

LightWave Acquisition beats Neoleukin Therapeutics on 3 of the 5 factors compared between the two stocks.

Get LightWave Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LWAC vs. The Competition

Export

Metric	LightWave Acquisition	Pharmaceutical Preparations Industry	Sector	NASDAQ Exchange
Market Cap	$309.52M	$962.05M	$2.99B	$12.49B
Dividend Yield	N/A	4.84%	15.26%	6.52%
P/E Ratio	N/A	1.61	14.94	24.58
Price / Sales	N/A	114.61	3,369.75	95.36
Price / Cash	N/A	22.05	49.05	49.23
Price / Book	N/A	8.23	5.97	6.45
Net Income	N/A	-$3.96M	-$200.52M	$335.81M
7 Day Performance	0.59%	-1.06%	0.54%	2.33%
1 Month Performance	0.79%	3.06%	1.15%	5.74%
1 Year Performance	N/A	47.87%	12.81%	25.63%

LightWave Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LWAC LightWave Acquisition	N/A	$10.29 +0.1%	N/A	N/A	$309.52M	N/A	N/A	N/A	High Trading Volume
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
AVTE Aerovate Therapeutics	N/A	$22.00 +0.9%	N/A	+93.1%	$637.67M	N/A	N/A	20	High Trading Volume
ELYM Eliem Therapeutics	N/A	$13.08 +3.3%	N/A	+907.8%	$389.16M	N/A	N/A	9	High Trading Volume
SBTX Silverback Therapeutics	N/A	$8.54 +6.5%	N/A	-48.2%	$307.94M	N/A	N/A	83	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LWAC) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LightWave Acquisition (LWAC) Competitors

LWAC vs. CALT, AVTE, ELYM, SBTX, and NLTX

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Summary

How does LightWave Acquisition compare to Aerovate Therapeutics?

Summary

How does LightWave Acquisition compare to Eliem Therapeutics?

Summary

How does LightWave Acquisition compare to Silverback Therapeutics?

Summary

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Summary

Media Sentiment Over Time

LWAC vs. The Competition

LightWave Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LightWave Acquisition (LWAC) Competitors

LWAC vs. CALT, AVTE, ELYM, SBTX, and NLTX

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Do institutionals and insiders believe in CALT or LWAC?

Does the media refer more to CALT or LWAC?

Do analysts rate CALT or LWAC?

Which has stronger valuation and earnings, CALT or LWAC?

Is CALT or LWAC more profitable?

Summary

How does LightWave Acquisition compare to Aerovate Therapeutics?

Do analysts prefer LWAC or AVTE?

Which has better valuation and earnings, LWAC or AVTE?

Does the media refer more to LWAC or AVTE?

Is LWAC or AVTE more profitable?

Summary

How does LightWave Acquisition compare to Eliem Therapeutics?

Do analysts rate LWAC or ELYM?

Which has stronger valuation & earnings, LWAC or ELYM?

Does the media prefer LWAC or ELYM?

Do insiders & institutionals believe in LWAC or ELYM?

Is LWAC or ELYM more profitable?

Summary

How does LightWave Acquisition compare to Silverback Therapeutics?

Does the media prefer SBTX or LWAC?

Do institutionals and insiders have more ownership in SBTX or LWAC?

Which has preferable valuation and earnings, SBTX or LWAC?

Is SBTX or LWAC more profitable?

Do analysts rate SBTX or LWAC?

Summary

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Which has better earnings and valuation, NLTX or LWAC?

Does the media prefer NLTX or LWAC?

Do analysts recommend NLTX or LWAC?

Do insiders and institutionals have more ownership in NLTX or LWAC?

Is NLTX or LWAC more profitable?

Summary

Media Sentiment Over Time

LWAC vs. The Competition

LightWave Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools